A new trading day began on Monday, with Olema Pharmaceuticals Inc (NASDAQ: OLMA) stock price up 3.53% from the previous day of trading, before settling in for the closing price of $5.95. OLMA’s price has ranged from $4.60 to $16.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -7.49%. With a float of $53.76 million, this company’s outstanding shares have now reached $57.29 million.
Let’s look at the performance matrix of the company that is accounted for 74 employees. In terms of profitability, gross margin is 85.67%, operating margin of -7213.69%, and the pretax margin is -6511.62%.
Olema Pharmaceuticals Inc (OLMA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Olema Pharmaceuticals Inc is 21.33%, while institutional ownership is 70.82%. The most recent insider transaction that took place on Jan 08 ’25, was worth 1,727,370. In this transaction 10% Owner of this company bought 300,000 shares at a rate of $5.76, taking the stock ownership to the 7,800,000 shares. Before that another transaction happened on Dec 17 ’24, when Company’s Director sold 700,761 for $6.75, making the entire transaction worth $4,730,137. This insider now owns 0 shares in total.
Olema Pharmaceuticals Inc (OLMA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.34% during the next five years compared to -105.28% drop over the previous five years of trading.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Trading Performance Indicators
Here are Olema Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.19, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.65 in one year’s time.
Technical Analysis of Olema Pharmaceuticals Inc (OLMA)
Olema Pharmaceuticals Inc (NASDAQ: OLMA) saw its 5-day average volume 1.05 million, a negative change from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 89.22%. Additionally, its Average True Range was 0.56.
During the past 100 days, Olema Pharmaceuticals Inc’s (OLMA) raw stochastic average was set at 16.72%, which indicates a significant decrease from 83.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.81% in the past 14 days, which was higher than the 81.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.42, while its 200-day Moving Average is $10.76. Nevertheless, the first resistance level for the watch stands at $6.45 in the near term. At $6.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.04. If the price goes on to break the first support level at $5.87, it is likely to go to the next support level at $5.58. Assuming the price breaks the second support level, the third support level stands at $5.29.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Key Stats
With a market capitalization of 420.93 million, the company has a total of 57,298K Shares Outstanding. Currently, annual sales are 0 K while annual income is -96,660 K. The company’s previous quarter sales were 0 K while its latest quarter income was -34,560 K.
